NBRV - Nabriva Therapeutics PLC Stock Price, Fair Value and News

Delayed

NBRV Stock Price

View Fullscreen

NBRV RSI Chart

NBRV Valuation

Market Cap

1.3M

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.04

EV/EBITDA

0.01

Price/Free Cashflow

-0.1

NBRV Price/Sales (Trailing)

NBRV Profitability

Operating Margin

-15.97%

EBT Margin

-183.46%

Return on Equity

-8.38%

Return on Assets

-520.46%

Free Cashflow Yield

-998.89%

NBRV Fundamentals

NBRV Revenue

Revenue (TTM)

29.6M

NBRV Earnings

Earnings (TTM)

-55.1M

Breaking Down NBRV Revenue

Last 7 days

-12.3%

Last 30 days

-7.9%

Last 90 days

-11.3%

Trailing 12 Months

725.1%

How does NBRV drawdown profile look like?

NBRV Financial Health

Current Ratio

0.38

Debt/Equity

5e-4

Debt/Cashflow

-37.53

NBRV Investor Care

Shares Dilution (1Y)

21.38%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	36.5M	29.6M	0	0
2022	34.4M	35.3M	35.6M	36.9M
2021	6.8M	14.5M	22.1M	28.9M
2020	8.6M	8.5M	2.9M	5.0M
2019	3.8M	3.5M	9.9M	9.5M
2018	11.2M	11.0M	10.0M	9.7M
2017	6.7M	6.0M	6.5M	5.3M
2016	4.6M	5.5M	5.1M	6.5M
2015	2.7M	3.1M	3.4M	3.8M
2014	0	0	0	2.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nabriva Therapeutics PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 29, 2023	schroeder theodore r	sold (taxes)	-646	1.5	-431	-
Jan 29, 2023	gelone steven p.	sold (taxes)	-210	1.5	-140	-
Jan 06, 2023	schroeder theodore r	sold (taxes)	-14.3	1.3	-11.00	chief executive officer
Jan 06, 2023	gelone steven p.	sold (taxes)	-6.5	1.3	-5.00	president and coo
Dec 31, 2022	gelone steven p.	sold (taxes)	-5.67	1.89	-3.00	president and coo
Dec 31, 2022	schroeder theodore r	sold (taxes)	-9.45	1.89	-5.00	chief executive officer
Dec 06, 2022	schroeder theodore r	sold (taxes)	-18.18	2.02	-9.00	chief executive officer
Dec 06, 2022	gelone steven p.	sold (taxes)	-8.08	2.02	-4.00	president and coo
Nov 30, 2022	schroeder theodore r	sold (taxes)	-11.25	2.25	-5.00	chief executive officer
Nov 30, 2022	gelone steven p.	sold (taxes)	-6.75	2.25	-3.00	president and coo

Which funds bought or sold NBRV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Bay Harbor Wealth Management, LLC	sold off	-100	-	-	-%

Are Funds Buying or Selling NBRV?

Are funds buying NBRV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBRV

No. of Funds

Unveiling Nabriva Therapeutics PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Nov 19, 2021	lincoln park capital fund, llc	7.96%	4,512,589	SC 13G
Feb 08, 2021	fmr llc	-	0	SC 13G/A
Feb 12, 2020	longitude capital partners ii, llc	4.5%	4,256,527	SC 13G/A
Feb 07, 2020	fmr llc	-	0	SC 13G
Dec 26, 2019	orbimed advisors llc	4.9%	4,644,600	SC 13D/A
Dec 06, 2019	orbimed advisors llc	5.9%	4,644,600	SC 13D/A

Nabriva Therapeutics PLC News

Latest updates

Nabriva Therapeutics PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-70.4%	2,243,000	7,590,000	10,571,000	9,153,000	9,191,000	8,020,000	9,261,000	8,862,000	8,243,000	2,529,000	2,460,000	1,291,000	487,000	789,000	333,000	6,920,000	525,000	1,703,000	797,000	461,000	847,000
Cost Of Revenue	104.5%	9,074,000	4,438,000	16,349,000	4,416,000	4,455,000	3,361,000	5,266,000	4,199,000	3,621,000	62,000	-	25,000	-	-	-	-	-	-	-	-	-
Costs and Expenses	-11.2%	14,267,000	16,065,000	32,902,000	20,355,000	19,590,000	19,578,000	22,145,000	19,676,000	19,625,000	15,977,000	20,728,000	14,508,000	14,940,000	20,977,000	22,403,000	24,119,000	21,501,000	20,947,000	31,676,000	53,386,000	18,554,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,501,000	20,947,000	31,676,000	53,386,000	18,554,000
S&GA Expenses	-54.4%	4,107,000	9,002,000	9,610,000	11,907,000	11,047,000	12,700,000	14,488,000	12,256,000	12,854,000	12,047,000	17,522,000	10,997,000	10,741,000	16,025,000	17,146,000	18,503,000	13,427,000	13,409,000	10,188,000	12,582,000	8,837,000
R&D Expenses	-58.6%	1,086,000	2,625,000	2,626,000	4,032,000	4,088,000	3,517,000	2,391,000	3,221,000	3,150,000	3,868,000	2,841,000	3,486,000	3,831,000	4,944,000	5,202,000	5,601,000	8,074,000	7,538,000	21,488,000	40,804,000	9,717,000
EBITDA Margin	-26.4%	-1.80	-1.42	-1.48	-1.26	-1.27	-1.32	-1.65	-2.44	-3.82	-8.74	-13.38	-24.66	-	-	-	-	-	-	-	-	-
Interest Expenses	100.5%	1,000	-194,000	1,257,000	-146,000	-198,000	-215,000	1,579,000	-221,000	-236,000	-221,000	158,000	256,000	251,000	1,024,000	877,000	709,000	904,000	899,000	114,000	8,000	7,000
Income Taxes	-	-	-	268,000	500,000	400,000	400,000	-59,000	-252,000	606,000	200,000	-37,000	-100,000	100,000	152,000	21,000	-29,000	-45,000	154,000	-259,000	-151,000	-48,000
Earnings Before Taxes	-38.6%	-12,062,000	-8,700,000	-22,469,000	-10,994,000	-10,689,000	-11,465,000	-13,117,000	-10,904,000	-11,148,000	-13,791,000	-17,893,000	-13,023,000	-15,322,000	-23,107,000	-23,024,000	-17,824,000	-21,752,000	-20,063,000	-31,083,000	-52,976,000	-17,836,000
EBT Margin	-26.7%	-1.83	-1.45	-1.51	-1.30	-1.31	-1.36	-1.69	-2.43	-3.85	-8.87	-13.79	-25.68	-	-	-	-	-	-	-	-	-
Net Income	-38.6%	-12,062,000	-8,700,000	-22,778,000	-11,514,000	-11,074,000	-11,819,000	-13,063,000	-10,652,000	-11,754,000	-13,981,000	-17,833,000	-12,951,000	-15,441,000	-23,259,000	-23,045,000	-17,795,000	-21,707,000	-20,217,000	-30,824,000	-52,825,000	-17,788,000
Net Income Margin	-25.8%	-1.86	-1.48	-1.55	-1.33	-1.32	-1.38	-1.71	-2.45	-3.89	-8.90	-13.82	-25.76	-	-	-	-	-	-	-	-	-
Free Cashflow	109.1%	511,000	-5,618,000	-1,625,000	-6,177,000	-13,039,000	-15,870,000	-6,118,000	-13,239,000	-18,574,000	-21,626,000	-13,364,000	-12,595,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	-56.5%	11.00	24.00	32.00	48.00	55.00	66.00	81.00	89.00	95.00	79.00	58.00	57.00	65.00	41.00	94.00	90.00	84.00	104	110	112	87.00
Current Assets	-58.0%	10.00	24.00	31.00	48.00	54.00	65.00	80.00	88.00	95.00	78.00	57.00	54.00	62.00	38.00	91.00	86.00	80.00	100	109	111	85.00
Cash Equivalents	21.4%	2.00	2.00	12.00	15.00	20.00	34.00	48.00	52.00	61.00	55.00	42.00	41.00	50.00	27.00	86.00	78.00	74.00	91.00	102	100	75.00
Inventory	-100.0%	-	9.00	10.00	17.00	16.00	16.00	15.00	16.00	10.00	9.00	6.00	6.00	5.00	4.00	1.00	0.00	-	-	-	-	-
Net PPE	-6.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	1.00	1.00	1.00
Liabilities	-6.3%	27.00	29.00	28.00	23.00	20.00	21.00	28.00	26.00	26.00	24.00	25.00	21.00	21.00	21.00	53.00	51.00	40.00	44.00	42.00	16.00	12.00
Current Liabilities	-6.4%	26.00	28.00	28.00	22.00	19.00	16.00	22.00	20.00	19.00	18.00	19.00	11.00	11.00	12.00	17.00	15.00	14.00	18.00	18.00	15.00	11.00
Long Term Debt	-0.3%	0.00	0.00	0.00	0.00	1.00	4.00	4.00	5.00	6.00	5.00	6.00	8.00	7.00	7.00	35.00	34.00	24.00	24.00	24.00	1.00	1.00
LT Debt, Current	-0.5%	0.00	0.00	5.00	6.00	7.00	4.00	4.00	3.00	2.00	3.00	2.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-0.3%	0.00	0.00	0.00	0.00	1.00	4.00	4.00	5.00	6.00	5.00	6.00	8.00	7.00	7.00	35.00	34.00	24.00	24.00	24.00	1.00	1.00
Shareholder's Equity	-	-	-	3.00	26.00	35.00	45.00	53.00	63.00	69.00	55.00	33.00	36.00	44.00	20.00	41.00	39.00	43.00	60.00	69.00	96.00	75.00
Retained Earnings	-1.8%	-673	-661	-652	-630	-618	-607	-595	-582	-571	-560	-546	-528	-515	-500	-476	-453	-435	-414	-393	-363	-310
Additional Paid-In Capital	0.0%	657	657	656	656	653	651	649	645	641	615	579	563	558	519	518	492	479	474	462	459	385
Shares Outstanding	0.9%	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	12.00	-	-	-	68.00	-	-	-	95.00	-	-	-	176	-	-	-	142

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	109.1%	511	-5,618	-1,625	-6,177	-13,039	-15,870	-6,118	-13,239	-18,574	-21,626	-13,364	-12,595	-17,264	-28,108	-15,487	-14,735	-21,045	-20,625	-22,231	-17,132	-17,021
Share Based Compensation	-90.2%	98.00	999	135	498	334	1,000	774	779	817	921	953	1,163	1,338	1,765	1,882	4,138	1,821	1,907	1,720	1,423	767
Cashflow From Investing	-1566.7%	-50.00	-3.00	-7.00	-104	-116	-36.00	-12.00	-	51.00	-120	-17.00	-9.00	-228	-20.00	200	188	-15.00	-42.00	-229	-4,092	-123
Cashflow From Financing	100.0%	-	-4,852	-659	1,108	-792	2,194	2,138	4,072	25,226	34,930	14,021	3,735	39,387	-30,219	23,395	19,252	3,749	9,679	24,327	46,378	3,159

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NBRV Income Statement

2023-06-30

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues:
Total revenues	$ 2,243	$ 9,191	$ 9,833	$ 17,211
Operating expenses:
Cost of revenues	(9,074)	(4,455)	(13,512)	(7,816)
Research and development expenses	(1,086)	(4,088)	(3,711)	(7,605)
Selling, general and administrative expenses	(4,107)	(11,047)	(13,107)	(23,747)
Total operating expenses	(14,267)	(19,590)	(30,330)	(39,168)
Loss from operations	(12,024)	(10,399)	(20,497)	(21,957)
Other (expense) income:
Other (expense) income, net	(39)	(92)	(70)	216
Interest income (expense), net	1	(198)	(194)	(413)
Loss before income taxes	(12,062)	(10,689)	(20,761)	(22,154)
Income tax expense	0	(385)	(1)	(739)
Net loss	$ (12,062)	$ (11,074)	$ (20,762)	$ (22,893)
Loss per share
Basic loss ($ per share)	$ (3.73)	$ (4.38)	$ (6.43)	$ (9.38)
Diluted loss ($ per share)	$ (3.73)	$ (4.38)	$ (6.43)	$ (9.38)
Weighted average number of shares:
Basic (in shares)	3,230,827	2,529,523	3,227,629	2,441,136
Diluted (in shares)	3,230,827	2,529,523	3,227,629	2,441,136
Product revenue, net
Revenues:
Total revenues	$ 2,574	$ 8,680	$ 10,135	$ 15,720
Collaboration revenue
Revenues:
Total revenues	0	96	29	725
Research premium and grant revenue
Revenues:
Total revenues	$ (331)	$ 415	$ (331)	$ 766

NBRV Balance Sheet

2023-06-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,182	$ 12,414
Restricted cash	73	123
Accounts receivable, net and other receivables	4,439	6,742
Inventory		9,676
Prepaid expenses	3,258	2,149
Total current assets	9,952	31,104
Property and equipment, net	246	280
Intangible assets, net	1	3
Other non-current assets	379	378
Total assets	10,578	31,765
Current liabilities:
Current portion of long-term debt	196	4,833
Accounts payable	14,026	5,431
Accrued expense and other current liabilities	11,981	17,341
Total current liabilities	26,203	27,605
Non-current liabilities:
Long-term debt	344	388
Other non-current liabilities	352	479
Total non-current liabilities	696	867
Total liabilities	26,899	28,472
Commitments and contingencies (Note 11)
Stockholders' (deficit) equity:
Ordinary shares, nominal value $0.01, 12,000,000 ordinary shares authorized at June 30, 2023 and December 31, 2022; 3,230,837 and 3,201,417 issued and outstanding at June 30, 2023 and December 31, 2022, respectively	32	32
Preferred shares, nominal value $0.01, 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; None issued and outstanding
Additional paid in capital	657,243	656,095
Accumulated deficit	(673,623)	(652,861)
Accumulated other comprehensive income	27	27
Total stockholders' (deficit) equity	(16,321)	3,293
Total liabilities and stockholders' (deficit) equity	$ 10,578	$ 31,765

About Nabriva Therapeutics PLC

WEBSITE	nabriva.com

Nabriva Therapeutics PLC Frequently Asked Questions

What is the ticker symbol for Nabriva Therapeutics PLC? What does NBRV stand for in stocks?

NBRV is the stock ticker symbol of Nabriva Therapeutics PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nabriva Therapeutics PLC (NBRV)?

As of Mon Oct 02 2023, market cap of Nabriva Therapeutics PLC is 1.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBRV stock?

You can check NBRV's fair value in chart for subscribers.

What is the fair value of NBRV stock?

You can check NBRV's fair value in chart for subscribers. The fair value of Nabriva Therapeutics PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nabriva Therapeutics PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBRV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nabriva Therapeutics PLC a good stock to buy?

The fair value guage provides a quick view whether NBRV is over valued or under valued. Whether Nabriva Therapeutics PLC is cheap or expensive depends on the assumptions which impact Nabriva Therapeutics PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBRV.

What is Nabriva Therapeutics PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 02 2023, NBRV's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBRV PE ratio will change depending on the future growth rate expectations of investors.